Skip to main content
. 2018 Jul 10;2018:3015891. doi: 10.1155/2018/3015891

Table 1.

Basal characteristics of patients.

Characteristic Lactulose LOLA Rifaximin Placebo P
n = 22 n = 22 n = 21 n = 22
Age (years) 50.1 ± 11.3 54.3 + 7.7 53.0 + 10.9 49.3 ± 9.5 0.31

Male gender, n (%) 14 (63.6) 14 (63.6) 10 (47.6) 17 (77.3) 0.25

CHILD A/B/C 7/10/5 7/13/2 9/10/2 5/15/2 0.54

Units of red cells concentrates 1.1 ± 1.4 1.4 + 1.2 1.0 + 1.1 1.4 ± 1.1 0.51

Cause of cirrhosis (n)
 Alcohol 8 11 9 11 0.65
 Hepatitis C 6 4 3 4
 NASH 4 7 5 4
 Other 4 0 4 3

MAP (mmHg) 70.4 ± 10.3 68.4 ± 11.6 67.8 ± 10.3 65.7 ± 10.5 0.50

Cardiac frequency (beats/min) 90.9 ± 15.6 95.4 ± 12.3 88.8 ± 7.8 94.9 ± 10.4 0.47

Time before endoscopy (hours) 8.0 ± 1.9 7.0 ± 1.0 7.6 ± 1.6 7.0 ± 1.0 0.07

Urea (mg/dl) 41.4 ± 20.6 39.5 ± 18.6 41.9 ± 22.2 44.8 ± 22.2 0.86

Creatinine (mg/dl) 0.92 ± 0.26 0.81 ± 0.18 0.83 ± 0.21 0.93 ± 0.22 0.20

Sodium (mEq/L) 137.6 ± 3.7 138.2 ± 4.6 138.5 ± 3.1 136.6 ± 3.7 0.39

Potassium (mEq/L) 4.0 ± 0.5 3.9 ± 0.5 4.0 ± 0.5 3.9 ± 0.4 0.62

Chlorine (mEq/L) 104.9 ± 4.0 101.9 ± 4.2 103.2 ± 5.6 104.3 ± 6.2 0.24

Albumin (mg/dl) 3.0 ± 0.7 3.2 ± 0.5 3.0 ± 0.6 2.9 ± 0.7 0.47

Bilirubin (mg/dl) 1.7 ± 1.4 1.7 ± 1.2 1.7 ± 1.3 2.1 ± 1.8 0.69

Hemoglobin (g/dl) 9.9 ± 4.7 8.6 ± 2.9 8.8 ± 2.7 8.3 ± 2.7 0.46

Hematocrit (%) 30.1 ± 14.6 26.3 ± 8.3 26.7 ± 7.9 25.7 ± 7.9 0.50

Platelets (10 9 cells/mcl) 130.6 ± 95.3 107.3 ± 34.4 131.1 ± 69.7 127.5 ± 71.9 0.65

Leucocytes (10 3 cells/mcl) 8.1 ± 5.4 7.6 ± 2.8 6.8 ± 2.6 9.0 ± 5.1 0.39

Neutrophils (10 3 cells/mcl) 6.0 ± 4.0 5.7 ± 2.3 5.2 ± 2.3 7.0 ± 4.6 0.41

Prothrombin time (sec) 17.3 ± 5.9 15.6 ± 3.9 17.8 ± 10.7 16.7 ± 4.0 0.73

INR 1.5 ± 0.5 1.3 ± 0.4 1.5 ± 0.9 1.4 ± 0.3 0.64

Variceal bleeding source
Esophageal/Gastric (n)
19/3 20/2 16/5 20/2 0.46

Rebleeding, n (%) 3 (13.6) 7 (31.8) 7 (33.3) 5 (22.7) 0.39

INR: international normalized ratio; LOLA: L-ornithine L-aspartate; MAP: mean arterial pressure; NASH: nonalcoholic steatohepatitis.

Statistical significance: P ≤ 0.05.